Skip to main
ACTU
ACTU logo

ACTU Stock Forecast & Price Target

ACTU Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Actuate Therapeutics has demonstrated significant progress in its clinical stage development, particularly with elraglusib, which has shown improved median overall survival and one-year survival rates in patients with metastatic pancreatic adenocarcinoma compared to standard treatment. The recent successful fundraising has strengthened the company’s balance sheet, providing the necessary financial flexibility to explore various regulatory pathways and manage critical operational costs associated with upcoming clinical studies. This combination of promising clinical data and enhanced financial position contributes to a positive outlook for the company's future development and potential market performance.

Bears say

Actuate Therapeutics Inc continues to face significant financial challenges, evidenced by its ongoing operational losses and reliance on external financing to fund its clinical development programs. The company's current cash reserves are insufficient to sustain its research activities over the long term, raising concerns about its ability to advance elraglusib through clinical trials. Additionally, the biopharmaceutical sector's competitive landscape, combined with the uncertainty surrounding clinical outcomes and regulatory approvals, contributes to a negative sentiment regarding Actuate Therapeutics's stock performance.

ACTU has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Actuate Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Actuate Therapeutics Inc (ACTU) Forecast

Analysts have given ACTU a Strong Buy based on their latest research and market trends.

According to 2 analysts, ACTU has a Strong Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Actuate Therapeutics Inc (ACTU)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.